See more : Broadpeak Société anonyme (ALBPK.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Ortin Laboratories Limited (ORTINLAABS.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ortin Laboratories Limited, a leading company in the industry within the sector.
- Rossell India Limited (ROSSELLIND.BO) Income Statement Analysis – Financial Results
- Alpha Partners Technology Merger Corp. (APTMU) Income Statement Analysis – Financial Results
- Vision Airships Inc. (VPSN) Income Statement Analysis – Financial Results
- Orange Polska S.A. (OPL.WA) Income Statement Analysis – Financial Results
- Polygiene Group AB (POLYG.ST) Income Statement Analysis – Financial Results
Ortin Laboratories Limited (ORTINLAABS.BO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
About Ortin Laboratories Limited
Ortin Laboratories Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders. It provides formulations, such as anti-diabetics, anti allergics, sedatives and tranquilisers, anti helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides; and anti-anginal and cardio vascular, and antifungal products. Its formulations also include chemo therapeutics, antacids and anti ulcerants, anti spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products. In addition, the company offers active pharmaceutical ingredient (API) intermediates, including anti retro viral, anti-diabetics, analgesics and antipyretics, anti-biotics, antifungal, antacids and anti ulcerants, and anti malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company provides services in the areas of process development, process and product characterization, analytical research and development, and assay development; and diagnostic services comprising development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs; and operates as a merchant exporter of pharmaceutical finished formulations. Ortin Laboratories Limited was incorporated in 1986 and is headquartered in Hyderabad, India.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 59.97M | 82.26M | 81.62M | 1.97B | 1.68B |
| Cost of Revenue | 46.73M | 60.79M | 56.06M | 1.87B | 1.58B |
| Gross Profit | 13.24M | 21.47M | 25.57M | 101.25M | 94.40M |
| Gross Profit Ratio | 22.08% | 26.10% | 31.32% | 5.13% | 5.64% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.05M | 17.64M | 15.67M | 60.16M | 37.19M |
| Other Expenses | -486.00K | -1.34M | -294.54K | -3.57M | -1.64M |
| Operating Expenses | 10.53M | 18.98M | 15.97M | 63.72M | 38.82M |
| Cost & Expenses | 57.26M | 79.77M | 72.02M | 1.94B | 1.62B |
| Interest Income | 196.00K | 32.93K | 496.00 | 1.52M | 753.00K |
| Interest Expense | 3.94M | 8.08M | 8.72M | 32.08M | 32.17M |
| Depreciation & Amortization | -2.50M | -2.94M | -2.85M | -19.55M | -17.53M |
| EBITDA | 5.21M | 5.43M | 12.45M | 57.08M | 73.11M |
| EBITDA Ratio | 8.68% | 6.61% | 15.26% | 2.89% | 4.36% |
| Operating Income | 2.71M | 2.50M | 9.60M | 37.53M | 55.58M |
| Operating Income Ratio | 4.51% | 3.03% | 11.76% | 1.90% | 3.32% |
| Total Other Income/Expenses | -3.81M | -7.80M | -8.23M | -30.35M | -37.20M |
| Income Before Tax | -1.11M | -5.30M | 1.36M | 7.19M | 18.38M |
| Income Before Tax Ratio | -1.84% | -6.44% | 1.67% | 0.36% | 1.10% |
| Income Tax Expense | -169.00K | -1.31M | -8.09M | 12.82M | 5.58M |
| Net Income | -936.00K | -3.99M | 9.45M | -5.64M | 12.80M |
| Net Income Ratio | -1.56% | -4.85% | 11.58% | -0.29% | 0.76% |
| EPS | -0.12 | -0.49 | 1.16 | -0.69 | 1.57 |
| EPS Diluted | -0.12 | -0.49 | 1.16 | -0.69 | 1.57 |
| Weighted Avg Shares Out | 8.13M | 8.13M | 8.15M | 8.13M | 8.13M |
| Weighted Avg Shares Out (Dil) | 8.13M | 8.13M | 8.15M | 8.13M | 8.13M |
Source: https://incomestatements.info
Category: Stock Reports